Health
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease – PRNewswire
/PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical…
LEXINGTON, Mass., March 24, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients with mild-to-moderate AD. Participants were evaluated for safety and tolerability, as well as cognitive function and markers of AD pathology. Professor Huntington Potter, together with Jonathan Woodcock, Timothy…
-
General22 hours agoa pivotal moment in Liberal power struggle
-
Noosa News22 hours agoTayla Harris stars as Melbourne defeats Essendon by 14 points
-
General20 hours agoRussia launches its biggest attack on Ukraine’s gas network since war began on the eve of winter
-
Business19 hours agoAmazon will stage a major comeback in the next 3 years. Here’s 1 reason why.